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Edited by Robert B. RussellAbstract In eukaryotes some surface proteins are attached to
the plasma membrane by a glycosylphosphatidylinositol (GPI)
anchor. A GPI-speciﬁc phospholipase D (GPI-PLD) activity has
been characterized and implicated in the regulation of anchoring,
thereby inﬂuencing the dispersal of anchored proteins or their
maintenance on the cell surface, and possibly in cell signalling.
Despite its biological and medical importance, little is known of
the structure of GPI-PLD. Here, a distant relationship between
the catalytic domains of GPI-PLD and some bacterial phospho-
lipases C is demonstrated. A model of the GPI-PLD catalytic
site sheds light on catalysis and highlights possibilities for design
of improved and more speciﬁc GPI-PLD inhibitors. The
databases contain hitherto unnoticed close homologues of GPI-
PLD from yeast and Dictyostelium discoideum.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Oneway inwhich eukaryotic cells anchor their proteins on the
outer surface of the plasma membrane is the glycosylphos-
phatidylinositol (GPI) anchor (reviewed in [1]). The structure of
the anchor varies between organisms but is typically of the form
EthN–P–Man3GlcN–PI, where EthN is ethanolamine, P is
phosphodiester, Man represents mannose, GlcN is glucosamine
andPI phosphatidylinositol [2,3]. The structuremaybemodiﬁed
by the addition of extra monosaccharide or ethanolamine moi-
eties and it is the carboxy terminus of the anchored protein that
forms an amide bond with the ethanolamine residue. The pro-
portion of proteins that are GPI anchored varies between or-
ganisms and tissues but the importance of GPI anchoring is
reﬂected in the dramatic eﬀects on growth and development
caused by mutations that aﬀect its synthesis [4,5]. Other mole-
cules may also be GPI anchored. Parasitic kinetoplasts like
Trypanosoma cruzi and Leishmania are particularly rich in non-* Fax: +44-151-795-4414.
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doi:10.1016/j.febslet.2004.05.071protein GPI-linked surface molecules that may have roles in
virulence and transmission [1].
While synthesis of GPI anchors is now relatively well under-
stood, the reasons, mechanisms and enzymes behind GPI an-
chor degradation remain far less clear. Endogenous activity
speciﬁc for GPI anchors is due to both phospholipases C [6] and
phospholipases D [7,8]. Interestingly, although GPI-speciﬁc
phospholipase D (GPI-PLD) is abundant in plasma, it does not
release surface proteins from cells: instead, cellular GPI-PLD
aﬀects the degree of anchoring of surface proteins, and hence
whether the proteins remain bound to the cell or are dispersed,
before their arrival at the cell surface [8,9]. Recent data suggest
that GPI-PLD can hydrolyze both intermediates along the
synthetic pathway of GPI anchors and GPI anchors already
attached to proteins [10]. The products ofGPI cleavagemay also
function as second messengers [11] so that GPI-PLD could also
have a signalling role [10]. Further stimulating interest in GPI-
PLDs are potential roles in importantmedical conditions. Thus,
GPI-PLD is overexpressed in tumour cells and mRNA levels
correlate with malignancy [12]. Indeed, GPI-PLD inhibitors
retarded growth of certain cancer cells at concentrations similar
to those required for enzyme inhibition [13]. Very recently, a
correlation between GPI-PLD levels and increased insulin re-
sistance in humans has been reported, suggesting that GPI-PLD
could be a chemotherapeutic target for atherosclerosis [14].
No crystal structures are available for GPI-PLDs and rela-
tively little can be inferred from simple sequence comparisons.
A b-propeller domain, homologous to that found in integrins,
can be conﬁdently detected in the C-terminal portion of the
protein [15]. Conservation of its calcium-binding motifs be-
tween integrins and GPI-PLD suggests that the C-terminal
domain is responsible for the experimentally observed calcium
binding [16] and probably functions to colocalize the enzyme
to the membrane surface, as for functionally analogous do-
mains in other phospholipases [17]. However, limited prote-
olysis shows that catalytic activity is associated with
approximately 275 N-terminal residues [18]. In other cases,
distant homology of various phospholipases with nucleases
[19,20] or phosphatases [21,22] has proved useful for the pre-
diction of catalytic residues. Unfortunately, standard database
searches reveal no homologues for the GPI-PLD catalytic
domain. Nevertheless, it is shown here, by sensitive sequence
comparisons and fold recognition, that the catalytic domain
of GPI-PLD bears an unexpected distant homology to bacte-
rial phosphatidylcholine-preferring phospholipases C. Struc-
ture modelling reveals an unperturbed trimetal catalytic site
architecture in GPI-PLDs and enables a possible catalyticblished by Elsevier B.V. All rights reserved.
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tighter binding, more speciﬁc inhibitors of GPI-PLD.2. Materials and methods
Sequences homologous to human GPI-PLD1 were sought in the
GenPept database using BLAST and PSI-BLAST [23] and the result-
ing sequence set was aligned with MUSCLE [24]. Jalview [25] was used
for alignment visualization and determination of the three maximally
diverse representatives of the GPI-PLD family. ESPRIPT [26] was
used for mapping sequence conservation onto structures. The Perl
script ps_scan, obtained from website of the PROSITE database of
protein sequence motifs and family alignment-derived sequence
proﬁles [27], was used for later motif-based sequence searches. Sear-
ches were made in the Smart [28] and Pfam [29] secondary databases,
which contain alignments of individual domains or protein sequences.
The N-terminal region of human GPI-PLD1 was submitted to the
META-server [30], which provides a portal to the leading fold
recognition methods, among them FFAS03 [31], 3D-PSSM [32],
Genthreader [33] and Bioinbgu [34], and yields consensus predictions
of improved reliability [35–37]. These fold recognition methods
search for known protein structures compatible with a target sequence
and employ sensetive sequence comparisons [31], sometimes combined
with consideration of inferred characteristics such as predicted
secondary structure and predicted exposure of residues to solvent
[32–34]. Secondary structure predictions were made using PSI-PRED
[38].
Modelling of the N-terminal portion of human GPI-PLD (Swissprot
accession number P80108; [39]), for which a fold recognition alignment
was produced, was performed with MODELLER 6 [40] using the
structures of Bacillus cereus phospholipase C (PDB code 1ah7; [41])
and the a-toxins of Clostridium absonum (PDB code 1olp; [42]) andFig. 1. Sequence alignment of bacterial PLCs and GPI-PLDs. Human GPI-
discoideum homologues (each with Genpept accession number), are aligned w
used as templates in model construction. The alignment of the PLCs is their s
used to make the ﬁnal GPI-PLD model. Identities within the sets of PLCs
sequences are additionally italicized. Numbering and actual secondary structu
and predicted secondary structure of human GPI-PLD1 shown below the alig
strands. The presumed zinc ligating residues are shown as white on black and
ligated. The ﬁgure was made with ALSCRIPT [66].Clostridium perfringens (PDB code 1ca1; [17]) as templates. Default
regimes of model reﬁnement by energy minimization and simulated
annealing were employed. Because of the low sequence similarity be-
tween target and template, a rigorous iterative modelling protocol was
employed in which 20 models were constructed and analyzed for each
alignment variant. These models were analyzed for packing and sol-
vent exposure characteristics with PROSA II [44] and VERIFY_3D
[45], and for stereochemical properties with PROCHECK [46]. Possi-
ble misalignments were highlighted by positive PROSA II proﬁles or
negative VERIFY_3D proﬁles which indicate portions of the model
that are atypical, compared to experimental protein structures, with
respect to solvent exposure of residues (both methods) or residue–
residue interactions (PROSA II). Variations in alignment of these re-
gions were tested and resulting proﬁle improvements taken as likely
indications of an increasingly accurate target–template alignment.
When no further improvements could be made, the model with the
highest PROSA II score was taken as the ﬁnal model. In the reliably
modelled region (Fig. 1), the human GPI-PLD plus yeast and Dicty-
ostelium discoideum homologues share 11–13% sequence identity with
the three templates. Protein structures were superimposed using
LSQMAN [47] and visualized using O [48]. Structure ﬁgures were
made using PyMOL [49] and secondary structures deﬁned with
STRIDE [50].3. Results and discussion
3.1. Sequence analyses and fold recognition
Iterative databases searches with human GPI-PLD1 (one of
two closely related human sequences [39]) as a probe revealed
a group of mammalian homologues sharing 79–95% sequence
identity with the human enzyme. Outside this group only twoPLD1 (with Swissprot accession number), and its S. cerevisiae and D.
ith the three bacterial PLCs (labelled with PDB code, species and name)
tructural alignment. The alignment between PLCs and PLDs is the one
or PLDs are shown in bold face. Residues well conserved between all
re of B. cereus PC-PLC are shown above the alignment with numbering
nment. Cylinders represent a- or 310-helices and arrows are used for b-
labelled according to which the three bound zincs are predicted to be
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visiae (accession NP_012403) and D. discoideum (accession
AAO50947), sharing 30% and 20% pairwise sequence iden-
tity, respectively, with the human enzyme. In the catalytic
region that comprises the ﬁrst 275 residues or so [18], the
pairwise sequence identity with the human enzyme is higher
at 36% and 25%, respectively. In each case, the sequences
derive from the respective genome projects [51,52] and there
is no information regarding function, although the existence
of ESTs corresponding to the D. discoideum sequence [53] is
proof of its expression. This seems to be the ﬁrst observation
of close relatives of GPI-PLDs, likely sharing the same cat-
alytic activity, outside higher eukaryotes. Although not the
main focus of this paper, it was curious to note that the
calcium-binding motifs within the b-propeller domain shared
by the homologous b-propeller domains of integrins and
mammalian GPI-PLDs are absent in the S. cerevisiae se-
quence. Further PSI-BLAST searches failed to reveal more
distantly related homologues.
More distant homologies, that might oﬀer a route to better
understanding the structure–function relationship in GPI-
PLDs, were sought through use of the Meta-server, a
resource enabling easy analysis of protein sequences by a
battery of more sensitive sequence comparisons and fold
recognition methods [30]. The catalytic site of GPI-PLDs is
known to reside in the N-terminal part of the protein [18].
Searches in the Smart database [28] showed that the integrin-
like repeats (smart00191) forming the C-terminal, calcium-
binding, non-catalytic b-propeller [15] commenced at residue
378. We therefore submitted the N-terminal 377 residues of
human GPI-PLD1 to the Meta-server. Several analyses, in-
cluding those based on sequence alone [31], produced top
scores for the structures of phospholipases C from B. cereus
and from clostridia species (these also known as the a-toxins).
These alignments extended from near the N-terminus to
around residue 260, corresponding well with the experimen-
tally determined size for a catalytically active GPI-PLD
fragment [18]. In several cases, diﬀerent putative structural
matches scored almost as highly, and other fold recognition
methods placed the PLCs in lower positions. Nevertheless,
the correctness of the structural correspondence between the
GIP-PLDs and the bacterial PLCs was assured by several
considerations. First of these was the results of the consensus
methods and their comparison to the results of ongoing
benchmarking eﬀorts [54]. The latest completed benchmark-
ing results suggest that the Shotgun on 3 consensus method
[35] currently distinguishes best between true and false neg-
atives. Human GPI-PLD1 N-terminal region scored 72 by
this method, well above the 55 scored by the best-scoring
incorrectly assigned fold. Second, there existed an obvious
functional similarity between the probe GPI-PLD sequence
and the top-scoring PLCs. Furthermore, in the initial fold-
recognition alignments six out of nine of the residues ligating
the three catalytic site zinc ions of the PLC structures were
conserved in the GPI-PLD1 sequence. A good correspon-
dence between the known secondary structure of the PLCs
and the predicted secondary structure of human GPI-PLD1
(Fig. 1) was also noted, particularly in the ﬁrst 150 residues
or so. Finally, GPI-PLDs have been experimentally proven to
bind catalytically essential zinc [16], although the estimated
10 Zn ions per monomer are well in excess of the three zincs
bound per monomer of bacterial PLC.3.2. Model building
The structures of the PLCs from B. cereus [41], C. absonum
[42] and C. perfringens [43] all scored comparably well and so
were all used as templates in model building of human GIP-
PLD1. Although known to resemble bacterial PLCs [19], P1
nuclease was not present in the fold recognition results and
was therefore not considered as a template. Successive struc-
tural determinations have highlighted the existence of open
(active; 3 bound zinc ions) and closed (inactive; 2 bound zinc
ions) forms of clostridial PLC [42]. However, the two loops
responsible for the largest structural diﬀerences between the
two forms (residues 63–87 and 135–149 in C. perfringens
numbering corresponding approximately to stretches 63–83
and 127–142 in B. cereus numbering – see Fig. 1) are very
diﬀerent in the PLDs (Fig. 1). The PLDs are substantially
shorter in the region of the ﬁrst loop but conversely have a
large insertion in the vicinity of the second. In any case, since
we wished to understand catalysis and substrate binding in the
PLDs, the open, active forms of the clostridial enzymes (PDB
codes 1olp [42] and 1ca1 [43]) were used as templates, along
with the B. cereus PLC structure (PDB code 1ah7; [41]).
Although only six of the nine zinc-ligating residues of the
PLCs were conserved in the initial, fold recognition-derived
alignments, examination of the PLD sequence showed that
suitable residues, conserved throughout the PLDs, could be
aligned with all the ligating residues in order to maintain all
three zinc binding sites (Fig. 1). The only diﬀerence between
the two sets of ligating residues lies at position 146 (B. cereus
PLC numbering) where the Glu that contributes to coordina-
tion of the second zinc ion in the PLCs is conservatively re-
placed by an Asp in the PLDs. This position is also occupied
by Asp in the P1 nucleases that are other known distant rel-
atives of bacterial PLCs [19] that maintain the trimetal site.
Since relatively few residues are absolutely conserved between
the closely related mammalian GPI-PLDs and the more dis-
tant S. cerevisiae and D. discoideum homologues, these align-
ment shifts could be made with conﬁdence. They also had
favourable eﬀects on the correspondence between predicted
PLD secondary structure and actual PLC secondary structure.
Absolute conservation between bacterial PLCs and GPI-PLDs
was also observed for Gly50 and Gly114. Structural inspection
revealed the explanation; these two residues lie at the heart of
the interface between their respective helices such that the
presence of any side chain would disrupt the helical packing.
Given that alignment errors are one of the major sources of
model inaccuracies, the conservation of metal ligands and Gly
residues was invaluable, providing reliable markers through-
out the sequence alignment. Nevertheless, signiﬁcant sources
of alignment uncertainty remained and were addressed
through construction and evaluation of multiple models for
alignment variants. One key issue was the alignment at the N-
terminus where, in the PLCs, the backbone of the very N-
terminal residue, a conserved Trp1, makes two interactions
with the third bound zinc. Since PLDs are signiﬁcantly longer,
and not well conserved at their N-terminus (Fig. 1), it seemed
unlikely that Met1 of human GPI-PLD1 would take the place
of PLC Trp1. Three other options were therefore tested
through model construction and analysis with either human
GPI-PLD1 His19 (as in the original fold recognition align-
ments), conserved Leu14 or conserved Trp7 aligned with Trp1
of the PLCs. Proﬁle analysis of the various models with
PROSA II [44] and VERIFY_3D [45] strongly favoured the
232 D.J. Rigden / FEBS Letters 569 (2004) 229–234choice of Leu14, the alternatives each leading to much worse
proﬁles for the N-terminal region. For example, by PROSA II,
employing a smoothing window of 11 residues, the mean
proﬁle values up to residue 30 for the best overall scoring
models were 0.94, 0.13 and 0.35, for the alignments with PLC
Trp1 of GPI-PLD1 His19, Leu14 and Trp7, respectively.
Circumstantial support for the choice of Leu14 came from the
position of conserved Trp132, replacing smaller residues in
PLCs. The side chain occupies part of the volume occupied by
Trp1 in the templates. The twin replacements of PLC Trp1
with Leu in the PLDs and PLC residue 127 with Trp may
therefore be seen as compensatory in terms of volume. Since
no template was available for the ﬁrst 13 residues, this portion
was not included in the modelling. Nor could any satisfactory
structure be obtained for the 12 residue insertion in PLDs
(residues 142–153 in human GPI-PLD1) relative to PLC
templates, which was also therefore omitted from the ﬁnal
model.
Although the fold recognition methods aligned GPI-PLD
sequence to the complete a-helical PLC domain, a sharp
boundary appeared during the modelling process between
PLD residues 1–170 (Fig. 1) and residues 171–260. While
PROSA II and VERIFY_3D proﬁles were generally favour-
able for the former portion, the C-terminal section was char-
acterized by positive PROSA II proﬁles and negative
VERIFY_3D proﬁles. Furthermore, two b-strands were pre-
dicted in the region 1–170 (Fig. 1), known to be essentially all
a-helical by reliable fold assignment, within the limits expected
by the accuracy of the technique of secondary structure pre-
diction. However, ﬁve were predicted for the following smaller
section comprising residues 171–260. Allied to a complete lack
of any conservation across PLCs and PLDs, these consider-
ations led to the conclusion that the region, GPI-PLD residues
171–260, must diﬀer suﬃciently from the PLCs such that
the latter no longer constitute useful templates for the region.
The ﬁnal model therefore comprises just the region 1–170
which, nevertheless, contains all catalytic and substrate binding
residues.
3.3. Implications for substrate binding and catalysis in
GPI-PLDs
Despite the obvious functional similarity between the GPI-
PLDs and the bacterial PLCs, they diﬀer in the location of
substrate cleavage. PLCs cleave phosphatidylcholine, as an
example, to produce phosphorylcholine and diacylglycerol: the
products of cleavage of the same substrate by PLD would be
choline and diacylglycerol-3-phosphate. How is the PLC vs.
PLD diﬀerence explained in this case? One possibility would be
that the phospho group binds diﬀerently so that a conserved
catalytic machinery attacks a diﬀerent side of the phospho
group. However, in the model of the catalytic site of human
GPI-PLD1, all zinc ligands present in the template PLC
structures are fully conserved, with the exception of a single
conservative replacement of Glu with Asp (Fig. 1). Structures
of bacterial PLCs with bound substrate analogues have re-
vealed that the phospho group is bound by all three zinc ions
[55]. From their conservation of the zinc sites, it therefore
seems likely that no major diﬀerences in substrate phospho
group position exist between GPI-PLDs and PLCs. Is it,
therefore, that substrate now binds in the opposite orientation,
the diacylglycerol portion of PLD substrate binding in the
region occupied by the phophocholine moiety in PLCs? Whilethere are sequence diﬀerences that could be interpreted as in-
creasing hydrophobicity of the GPI-PLD1 pocket, within the
area that binds phosphocholine in PLC, in a way consistent
with diacylglycerol binding, such analysis may not be reliable
in this case; the homology with templates is very distant and
the shape and nature of the binding site could be changed
signiﬁcantly by the missing pieces of the model, the very N-
terminus and the 12 residue deletion. Without stronger evi-
dence, the more conservative prediction that the substrate
binds similarly overall to both PLCs and PLDs should stand.
Could the explanation for the PLC vs. PLD diﬀerence
therefore lie in diﬀerences in catalytic machinery? Since the
visualization of the trimetal centres in PLCs and the distantly
homologous P1 nuclease [19], various catalytic mechanisms
have been proposed [55–57]. Kinetic data have been obtained
that favour activation of a nucleophilic water molecule by a
protein side chain rather than one of the zinc ions [58]. Site-
directed mutagenesis of conserved acidic residues of the B.
cereus PLC catalytic site has also been reported [58,59] which
strongly implicated Asp55 (B. cereus PLC numbering), con-
served between PLCs and their distant relative Penicillium
citrinum P1 nuclease, as being responsible for activation of the
water molecule which then nucleophilically attacks the sub-
strate (Fig. 2(a) and (c)). The nucleophilic water molecule has
been tentatively identiﬁed as one observed crystallographically
in complexes of B. cereus PLC, both wild-type [55] and Asp55
Asn mutant [57], with substrate analogues (Fig. 2(a)). The
water in question is also hydrogen-bonded to Glu4 which is
absent in the clostridial PLCs, probably being substituted in
these enzymes by conserved Asp2. In contrast, the GPI-PLDs
lack acidic side chains in the area, other than Asp68 that
corresponds to B. cereus PLC Asp55. However, examination
of the model reveals a new conserved acidic residue near to
Asp68 in the form of Glu85 (Figs. 1 and 2(b)). This is a dra-
matically non-conservative replacement for Phe or Tyr in the
bacterial PLCs (Fig. 1). The conservation of Glu85, reliably
placed in the catalytic site through its three residue separation
from a zinc ligand (Fig. 1) and by the overlap between pre-
dicted GPI-PLD a-helices and a 310 helix in the templates
(Fig. 1), is suggestive of an important functional role. This
seems unlikely to be direct binding of substrate, since it is
predicted to be positioned near the negatively charged phos-
pho group (Fig. 2(b)); the nearest positively charged region of
the GPI substrate is the amino group of the glucosamine which
cannot bind so close to the site of catalysis. Instead, the po-
sition of Glu85 is consistent with its participation in hydrogen
bonding, in conjunction with Asp68, to a modelled catalytic
water molecule (Fig. 2(b) and (d)). In simple terms, it would
therefore functionally substitute Glu4 (B. cereus) or Asp2
(clostridia) of the PLCs. Crucially, however, the water mole-
cule would be diﬀerently placed with respect to the phospho
group of the substrate (Fig. 2) and positioned so that its nu-
cleophilic attack on substrate would lead to PLD-type cleavage
(Fig. 2(d)) rather than PLC-type cleavage (Fig. 2(c)). Thus, the
prediction is that Asp55/68 conserved between the PLCs and
PLDs activates water for subsequent nucleophilic attack. The
diﬀerence between the two phospholipase classes lies in other
conserved acidic residues which contribute to suitably posi-
tioning that water molecule. In PLCs, the relevant water
molecule may well have been visualized crystallographically
[55,57]. In the case of PLDs only a model is available, but it is
enough to suggest that if Glu85 contributes to binding of the
Fig. 2. Comparison of predicted catalytic mechanisms in bacterial
PLCs and GPI-PLDs. Comparison of the catalytic sites of (a) B. cereus
PLC bound to phosphonate substrate analogue (PDB code 1p6d [57])
and (b) human GPI-PLD1 (modelled). In each case, zinc ions (labelled
1–3 according to the numbering of [57]) are shown as pink spheres and
the predicted nucleophilic water molecules as red sphere, bound by
hydrogen bonds (grey dotted lines). Protein residues binding to either
zinc or water are shown as sticks and are labelled. The substrate an-
alogue is shown as ball and stick. In (b) small adjustments have been
made to the substrate analogue position in order to ameliorate minor
steric clashes with the modelled water molecule. The choline portion of
the analogue, not present in the substrates of GPI-PLD, is not shown
in (b): an asterisk marks the position of attachment of the inositol
moiety. A schematic comparison of bacterial PLCs and GPI-PLDs
showing how diﬀerently the position of nucleophilic water mole-
cules could lead to diﬀerent modes of phospholipase activity is shown
in (c) B. cereus PLC and (d) human GPI-PLD1. DAG stands for
diacylglycerol and R for the remainder of the GPI anchor.
D.J. Rigden / FEBS Letters 569 (2004) 229–234 233nucleophilic water molecule then the water must be positioned
so as to lead to PLD-type substrate hydrolysis. Glu85 is thus
highlighted as a prime target for study by site-directed muta-
genesis. The results of such study would provide a valuable test
of the proposed mechanism which, at this stage, is purely
hypothetical.
3.4. Prospects for drug design
The trimetal architecture shared by the catalytic sites of
bacterial PLCs and GPI-PLDs and relatives is unusual. The
current PFAM [29] entry for the bacterial PLC family
(PF00882) shows 32 sequences, exclusively bacterial. The S1–
P1 nuclease entry (PF02265) shows a distribution that includes
36 eukaryotic sequences, none mammalian, and 7 bacteria. In
order to examine further whether the GPI-PLD is the only
human representative of this architecture, we formulated a
motif, based on the most conserved positions, that would re-
trieve all known members of the bacterial PLCs, the P1 nuc-
leases and the GPI-PLDs and relatives. Accordingly, a motif
search was carried out in the Swissprot database [60] using the
following motif [LIFVMW]-x(4)-H-x(3)-D-[LIVMFTCA]-
x(2,4)-H-x(8,39)-H-x(3)-[DE], which covers ligands of all threezinc atoms and is represented in B. cereus PLC, for example,
by residues 117–146. In humans, this motif matches, along
with the GPI_PLDs four other proteins, all, from their an-
notations, unlikely to have the trimetal catalytic sites – a cal-
cium channel subunit (Swissprot entry CCAB_HUMAN), a
transcription factor (FXJ1_HUMAN), a Ras activating pro-
tein (SNGP_HUMAN) and a zinc ﬁnger protein
(ZN92_HUMAN). Of course, Swissprot does not include all
human proteins, but the motif search results support the idea
that the GPI-PLDs are the only human proteins with the PLC-
PLD-P1 nuclease class trimetal catalytic site.
The probable uniqueness of the catalytic site architecture in
humans has important consequences for the design of GPI-
PLD inhibitors for use as treatments for cancer [12,13] or,
possibly, atherosclerosis [14]. As the recently designed B. ce-
reus PLC inhibitors [61] show, metal ions oﬀer particular op-
portunities for inhibitor design. Hydroxamic acids derivatives
are particularly useful for zinc ligation [62]. Given the simi-
larities described above, it is highly likely that the B. cereus
PLC inhibitors described [61] will be active towards GPI-
PLDs. Other classes of bacterial PLC inhibitors, not speciﬁ-
cally those targeted at bound metal, have also been developed
and may be useful starting points for GPI-PLD inhibitor de-
sign [63]. Indeed, in one case where they have been tested on
GPI-PLD, potent inhibition was observed [13]. Knowledge of
the catalytic site architecture of GPI-PLDs will certainly help
optimize these and the limited number of other known GPI-
PLD inhibitors [64]. At present sub-micromolar inhibition of
GPI-PLD, an important drug target [12–14], has not been re-
ported. One obvious route might be the combination of the
hydroxamic acid derivatives, targeted to the bound metal, with
features of product analogue which occupy other parts of the
substrate binding site.4. Conclusions
The biological and medical importance of GPI-PLD is be-
coming ever more apparent so that the lack of structural in-
formation for the enzyme will increasingly be felt. Until a
crystal structure is available the distant homology with bac-
terial PLCs reported here, and the catalytic site model that
could thereby be constructed, can be used to guide experi-
mental work. Speciﬁcally, the prediction that GPI-PLD con-
tains a zinc trimetal centre, once conﬁrmed experimentally,
should facilitate inhibitor design, while the catalytic mecha-
nism tentatively proposed here can be readily tested by
site-directed mutagenesis. The GPI-PLD homologues in
S. cerevisiae and D. discoideum are interesting subjects for
future study given the diﬀerent role of GPI-proteins in the
former [65] and the ease of genetic manipulation of the latter.References
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